Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Drug Discovery 2, 613–623 (1 August 2003) | doi:10.1038/nrd1152
Pharmacophylogenomics: genes, evolution and drug targets
Abstract
Phylogenomics, which advocates an evolutionary view of genomic data, has been useful in the prediction of protein function, of significant sequence and structural elements, and of protein interactions and other relationships. Although such information is important in characterizing individual pharmacological targets, evolutionary analyses also indicate new ways to view the overall space of gene products in terms of their suitability for therapeutic intervention. This view places increased emphasis on the comprehensive analysis of the evolutionary history of targets, in particular their orthology and paralogy relationships, the rate and nature of evolutionary change they have undergone, and their involvement in evolving pathways and networks.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
